# Comparison of Nefopam-Based Patient-Controlled Analgesia with Opioid-Based Patient-Controlled Analgesia for Postoperative Pain Management in Immediate Breast Reconstruction Surgery: A Randomized Controlled Trial

**Authors:** Jaewon Huh, Noori Lee, Minju Kim, Hoon Choi, Deuk Young Oh, Jangyoun Choi, Wonjung Hwang

PMC · DOI: 10.3390/jcm13123490 · 2024-06-14

## TL;DR

This study compares pain management using nefopam and opioids after breast reconstruction surgery, finding similar effectiveness with fewer opioid needs.

## Contribution

Demonstrates that nefopam-based PCA provides non-inferior pain relief compared to opioid-based PCA in postoperative breast reconstruction patients.

## Key findings

- Nefopam-based PCA showed non-inferior analgesic efficacy compared to fentanyl alone.
- Total opioid consumption was significantly lower in groups using nefopam.
- No significant differences in opioid-related complications were observed across groups.

## Abstract

Background/Objectives: Immediate breast reconstruction surgery (BRS) often leads to significant postoperative pain, necessitating effective analgesia. This study aimed to compare the analgesic efficacy of patient-controlled analgesia (PCA) containing nefopam with that of PCA containing opioids alone in patients undergoing BRS. Methods: A prospective, double-blind, randomized controlled trial was conducted on 120 patients undergoing immediate BRS after mastectomy. Patients were randomly allocated to receive PCA with fentanyl alone (Group F: fentanyl 10 mcg/kg), fentanyl and nefopam (Group FN: fentanyl 5 mcg/kg + nefopam 1 mg/kg), or nefopam alone (Group N: nefopam 2 mg/kg). Pain intensity (expressed in VASr and VASm), opioid consumption, and opioid-related complications were assessed. Results: PCA with nefopam, either alone or in combination with opioids, demonstrated non-inferior analgesic efficacy compared to PCA with fentanyl alone. At 24 h postoperatively, the VASr scores were 2.9 ± 1.0 in Group F, 3.1 ± 1.2 in Group FN, and 2.8 ± 0.9 in Group N (p = 0.501). At the same timepoint, the VASm scores were 4.1 ± 1.2 in Group F, 4.5 ± 1.5 in Group FN, and 3.8 ± 1.4 in Group N (p = 0.129). Significant differences among the three groups were observed at all timepoints except for PACU in terms of the total opioid consumption (p < 0.0001). However, there were no significant differences in opioid-related complications among the three groups. Conclusions: PCA with nefopam, whether alone or in combination with opioids, offers non-inferior analgesic efficacy compared to PCA with fentanyl alone in patients undergoing immediate BRS.

## Linked entities

- **Chemicals:** nefopam (PubChem CID 4450), fentanyl (PubChem CID 3345)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Diseases:** Pain (MESH:D010146), Postoperative Pain (MESH:D010149)
- **Chemicals:** Nefopam (MESH:D009340), fentanyl (MESH:D005283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11204651/full.md

---
Source: https://tomesphere.com/paper/PMC11204651